摘要
目的:研究弥漫大B细胞淋巴瘤(DLBCL)患者Ki-67蛋白表达检测的预后意义。方法:选取笔者所在医院2017年6月-2018年6月收治的60例弥漫大B细胞淋巴瘤患者为研究对象,均予以免疫组织化学检测法,同时检测Ki-67蛋白的表达,并予以CHOP治疗方案,观察分析Ki-67蛋白表达对患者预后的影响。结果:经检测,Ki-67蛋白低表达患者22例,Ki-67蛋白高表达患者38例。Ki-67蛋白低表达患者与Ki-67蛋白高表达患者年龄、性别、结外病变、IPL评分、LDH值、临床分期对比差异无统计学意义(P>0.05)。经过治疗后Ki-67蛋白低表达组生存时间长于Ki-67蛋白高表达组,治疗总有效率高于Ki-67蛋白高表达组,差异均有统计学意义(P<0.05)。结论:针对DLBCL可依据Ki-67蛋白表达情况评价患者的预后情况,Ki-67蛋白表达越高说明患者预后越差,故在临床上具有应用价值。
Objective: To investigate the prognostic significance of Ki-67 protein expression in patients with diffuse large B-cell lymphoma. Method: Sixty patients with diffuse large B-cell lymphoma(DLBCL) admitted to our hospital from June 2017 to June 2018 were enrolled in the study. Immunohistochemistry was performed to detect the expression of Ki-67 protein. The CHOP treatment protocol was also used to observe the effect of Ki-67 protein expression on the prognosis of patients. Result: After test, there were 22 patients with low expression of ki-67 protein and 38 patients with high expression of ki-67 protein. There was no significant difference in age, sex, extranodular lesion, IPL score, LDH value, clinical stage in patients with low expression of Ki-67 protein and patients with high expression of Ki-67 protein(P>0.05). After treatment, the survival time of Ki-67 protein low expression group was longer than that of Ki-67 protein high expression group, and the total effective rate of treatment was higher than that of Ki-67 protein high expression group, the differences were statistically significant(P<0.05). Conclusion: The prognosis of patients with DLBCL can be evaluated according to the expression of Ki-67 protein. The higher the expression of Ki-67 protein, the worse the prognosis of patients, so it has clinical application value.
作者
马礼勇
MA Liyong(Qujing First People’s Hospital,Qujing 655000,China)
出处
《中外医学研究》
2020年第4期53-55,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
